


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**LIFE HEALTHCARE GROUP LIMITED**  
**蓮和醫療健康集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 928)**

**VOLUNTARY ANNOUNCEMENT**  
**STRATEGIC COOPERATION ON BIG DATA APPLICATION FOR**  
**HEALTHCARE MANAGEMENT**

**STRATEGIC COOPERATION**

On 31 March 2020, 蓮和(北京)醫療科技有限公司 (Life Healthcare (Beijing) Company Limited\*) (“**Beijing Life Healthcare**”), a subsidiary which the Company has effective control by virtue of certain structured contracts, entered into a strategic cooperation agreement with 中國衛生信息與健康醫療大數據學會慢病大數據應用發展聯盟 (The Alliance of Chronic Disease Big Data Application of the Chinese Medical Information and Big Data Association\*) (the “**Alliance**”), under which (the “**Cooperation**”).

The Cooperation has a term up to 31 December 2023.

Under the scope of the Cooperation, the parties agreed to cooperate on real-time collection and classification of data and explore new healthcare management methods and the parties will enter into individual contracts on a project basis to realise the strategic goal of the Cooperation. Under the ambit of such scope, on 31 March 2020, Beijing Life Healthcare entered into a project cooperation agreement with 中關村國衛健康大數據研究院 (Zhongguancun National Health Big Data Research Institute\*) (the “**Institute**”), a member of the Alliance, pursuant to which the parties agreed to set up trial platforms in different locations to explore, test and implement big data collection and healthcare management (the “**Project**”). Under the scope of the Project, the Group will contribute RMB2,000,000 and provide products of RMB4,000,000, in aggregate to support the Project.

The term of the Project will be up to 31 March 2023.

## **INFORMATION ON THE PARTIES**

### **The Company**

The Group is principally engaged in healthcare services business, money lending business and securities trading and investment business.

### **Beijing Life Healthcare**

Beijing Life Healthcare is a subsidiary which the Company has effective control by virtue of certain structured contracts; and is principally engaged in the provision of healthcare services.

### **The Alliance**

The Alliance is the first alliance focusing on chronic disease big data applications. Under the guidance of the Chinese Medical Information and big data Association (中國衛生信息與健康醫療大數據學會) (the “**Association**”), the Alliance, a branch under the Association, commits to build a collaborative and interactive platform in the field of chronic disease prevention and treatment and big data management, integrate chronic disease-related data resources, and collaborate with relevant enterprises and research institutions, by carrying out academic exchanges, pilot research, technical training and innovative business, to provide data support and planning consultation for scientific research, industrial reform and model innovation as well as promote the development of prevention and management of chronic disease. To the best knowledge, information and belief of the Directors, after reasonable enquiries, the Alliance and its ultimate beneficial owners are independent of and not connected with the Company or any of its connected persons.

### **The Institute**

The Institute is an academic and research institute for the application of big data in healthcare services. To the best knowledge, information and belief of the Directors, after reasonable enquiries, the Institute and its ultimate beneficial owners are independent of and not connected with the Company or any of its connected persons.

## **REASONS AND BENEFITS OF THE COOPERATION AND THE PROJECT**

The collaboration with the Alliance and the Institute will give full play to the technological strength of the Group in the Internet of Things and resources on the medical and health industry, and establish a health and medical big data platform thereby creating a new health management model to carry out continuous health management of patients, and provide a venue for the Group to develop its products and services. The Cooperation and the Project are believed to establish a milestone for the corporate development of the Group; while the business model and scale are believed to be enhanced with the long-developed competitive advantage of the Group.

The Directors consider that the Cooperation and the Project are being carried out in the ordinary and usual course of business of the Group, on normal commercial terms and are in the interests of the Company and the shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

As the applicable percentage ratios in respect of the Cooperation and the Project are below 5%, the Cooperation and the establishment of the Project do not constitute a notifiable transaction for the Company under Chapter 14 of the Listing Rules. This announcement is made by the Company on a voluntary basis.

By order of the Board  
**Life Healthcare Group Limited**  
**Man Wai Lun**  
*Executive Director*

31 March 2020

*As at the date of this announcement, the Board comprises:*

*Executive Directors:*

Mr. Xu Xueping (*Chairman*)  
Mr. Man Wai Lun  
Mr. Yang Zhiying

*Independent Non-executive Directors:*

Mr. Liu Xinghua  
Mr. Zheng Chunlei  
Mr. Cheng Chun Man

*Non-executive Director:*

Ms. Shan Hua